16 November, 2022
HER2DX, one of the best inventions of 2022 according to TIME magazine
Every year, TIME draws up a list of the best inventions, those that according to the prestigious magazine “make the world better, smarter and even more fun”. In the 2022 ranking, they have included, in the “Medical Care” category, HER2DX, a genomic test that predicts survival and the possibility of responding to treatments in HER2-positive breast cancer patients in their earliest stages, the first genomic test created worldwide for this disease.
This test has been developed by REVEAL GENOMICS, S.L., a spin-off of Clínic Barcelona, the IDIBAPS, the Universitat de Barcelona (UB) and the Vall d’Hebron Institute of Oncology (VHIO). This is a tool that is currently offered to barnaclínic+ patients and that allows for avoiding unnecessary treatments.
TE PUEDE INTERESAR…
· A new genomic test allows personalising the treatment of HER2+ breast cancer
· A new molecular test detects genetic abnormalities in tumours and improves customised cancer diagnosis and treatment
· Genetic study for cancer risk detection
HOW DOES TIME CHOOSE THE BEST INVENTIONS OF 2022?
When creating this list, the magazine requests nominations from its editors and co-responsible persons throughout the world and, in addition, enables the online application of candidacies. Once the applications have been compiled, the publication evaluates each one of the inventions in aspects such as impact, originality, creativity and efficiency. To include HER2DX in the list of the best inventions of 2022, TIME magazine believes that this diagnostic test “contributes to obtaining better results for early-stage patients, but could also lead to more personalised approaches for breast cancers in an advanced stage”.
For Dr Patricia Villagrasa, co-founder and CEO of REVEAL GENOMICS, TIME’s recognition “endorses our first product and encourages us to continue with our vision of the future of precision oncology. We created REVEAL GENOMICS to develop unique solutions with proven clinical utility, and HER2DX exemplifies our potential. The immediate goal of REVEAL GENOMICS is to ensure that HER2DX is globally available and reaches all HER2+ breast cancer patients”.
Dr Aleix Prat, head of the Translational genomics and targeted therapies in solid tumours group at IDIBAPS, co-founder and CSO of REVEAL GENOMICS and oncologist at barnaclínic+, comments that “HER2+ breast cancer is a health problem that affects more than 400,000 women a year. To date, we did not have any tool that would help the oncologist and the patient to make key therapeutic decisions for her life. Consequently, many patients experienced either over or under-treatment. For this reason, we developed HER2DX, the first test that helps to optimize the treatment for this type of patient”.
“HER2+ breast cancer is a health problem that affects more than 400,000 women a year. To date, we did not have any tool that would help the oncologist and the patient to make key therapeutic decisions for her life. Consequently, many patients experienced either over or under-treatment. For this reason, we developed HER2DX, the first test that helps to optimize the treatment for this type of patient”
Dr Aleix Prat, head of the Translational genomics and targeted therapies in solid tumours group at IDIBAPS, co-founder and CSO of REVEAL GENOMICS and oncologist at barnaclínic+
WHAT DOES THE HER2DX TEST CONSIST OF?
HER2DX is the world’s first diagnostic test explicitly created for HER2+ breast cancer. Marketed by REVEAL GENOMICS since January 2022, the HER2DX is a standardised 27-gene expression test for patients with early-stage HER2+ breast cancer.
The test provides a prognostic and predictive report based on clinical and genomic data. The test integrates clinical information (tumour size and node status) with biological information (immune infiltration, luminal differentiation, tumour cell proliferation, and expression of HER2 chromosome amplicon 17q12-21, including the ERBB2 gene).
HER2DX provides:
- A recurrence risk score (high or low): the risk of recurrence in patients with newly diagnosed HER2+ breast cancer.
- A pCR probability score (high, medium, or low): the probability that a patient will respond to anti-HER2-based treatment prior to surgery.
- An ERBB2 score (high, medium, or low): the quantitative expression of ERBB2 mRNA